FDA Hands BeOne, Taiho Approvals for Blood Cancers

Why It Matters

The clearances give BeOne a foothold in a niche lymphoma market and position Inqovi as an oral, less‑intensive AML option for elderly patients, reshaping competitive dynamics in blood‑cancer therapy.

Key Takeaways

• Beqalzi receives FDA accelerated approval for mantle‑cell lymphoma (MCL)
• Beqalzi shows 52% overall response, 16% complete responses in trial
• Inqovi approved with Venclexta for first‑line AML in patients ≥75
• Inqovi/Venclexta regimen achieved 41.6% complete remission in ASCERTAIN‑V
• Beqalzi aims to expand into CLL and AML, competing with Venclexta

Pulse Analysis

The BCL‑2 inhibitor class has been dominated by AbbVie’s Venclexta, a $2.8 billion blockbuster used across chronic lymphocytic leukemia and acute myeloid leukemia. BeOne’s Beqalzi enters this space with a next‑generation molecule that promises greater potency, selectivity, and a shorter half‑life, enabling more flexible dosing. By securing accelerated approval for mantle‑cell lymphoma—a niche without a dedicated BCL‑2 therapy—Beqalzi sidesteps direct competition while leveraging the same mechanistic pathway that has proven clinical value. This strategic entry point could accelerate label expansion into broader non‑Hodgkin lymphoma, CLL, and AML indications, where it will directly challenge Venclexta’s market share.

The pivotal phase 1/2 BGB‑11417‑201 study underpins Beqalzi’s approval, reporting a 52% objective response rate and 16% complete remissions in heavily pre‑treated MCL patients. These outcomes suggest the drug can deliver meaningful efficacy where existing therapies have failed, while its pharmacokinetic profile may reduce adverse events linked to prolonged exposure. Beqalzi’s upcoming CELESTIAL‑TNCLL trial will test a combination with BeOne’s BTK inhibitor Brukinsa against Venclexta plus Roche’s anti‑CD20 antibody Gazyva, potentially establishing a new standard of care for first‑line CLL patients.

Taiho Oncology’s Inqovi, an oral formulation of decitabine paired with cedazuridine, now gains FDA endorsement for use with Venclexta in newly diagnosed AML patients aged 75 or older who cannot tolerate intensive chemotherapy. The ASCERTAIN‑V study demonstrated a 41.6% complete remission rate, offering a less‑burdensome, fully oral alternative to traditional intravenous hypomethylating agents. This approval addresses a critical unmet need for elderly AML patients, reducing clinic visits and improving quality of life. As oral regimens gain traction, Inqovi could reshape first‑line AML treatment algorithms, prompting competitors to accelerate their own oral‑therapy pipelines.